SBI-183
Pre-clinical- Indications
- breast cancer, kidney cancer, pancreatic cancer
Company intelligence / Profile preview
Sapphire Biotech developed small molecule inhibitors targeting QSOX1 for potential use in cancer diagnosis and therapy. Their lead compound(s) were at pre-clinical stage prior to acquisition. They received a $395,880 SBIR Phase I grant from the National Cancer Institute to support this work.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sapphire Research.